Intas Reports Results of Razumab (biosimilar, ranibizumab) in the Real-world Study for the Treatment of Diabetic Macular Edema in India
Shots:
- The real-world study of Razumab (biosimilar, ranibizumab) vs Accentrix in patients with DME showed similar effectiveness & safety, baseline characteristics, duration of follow-up & mean number of inj. were similar in both groups
- The primary outcome was the improvement in mean BCVA from baseline to 3mos. then remained stable @6mos. & 1yr. mean reduction in CMT, no differences b/w both groups with no patients suffered drug-related systemic AEs & no differences in visual & anatomical outcomes in treatment-naive patients
- Accentrix is marketed as Lucentis in the US & is commercialized by Genentech. Ranibizumab is an anti-VEGF antibody fragment delivered via IV inj. to treat ophthalmic conditions
Ref: The Center For Biosimilar | Image: Intas
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
